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Anxiety, stress, and low mood are closely related and may contribute to depressive
symptoms. Among non-pharmacological solutions to improve subclinical mood
symptoms and resilience to stress, natural products such as saffron—identified as
promising following preliminary beneficial effects in major depressive disorder—represent
a relevant strategy. This study aimed to assess the efficacy of 8 weeks’ supplementation
with 30mg standardized saffron extract on emotional well-being in healthy adults with
subclinical feelings of low mood and anxiety and/or stress and evaluate the acute
effect of saffron in response to a lab-based psychosocial stressor. The study adopted
a double-blind, randomized, parallel groups design in which 56 healthy male and female
individuals (18–54 years) received either a saffron extract or a placebo for 8 weeks.
Chronic effects of saffron on subjective anxiety, stress, and depressive feelings were
assessed using a questionnaire battery [including Profile of Mood State-2, (POMS)] and
acute effects in response to a lab-based psychosocial stressor were measured through
psychological and physiological parameters. Urinary crocetin levels were quantified.
Participants who received the saffron extract reported reduced depression scores
and improved social relationships at the end of the study. Urinary crocetin levels
increased significantly with saffron supplementation and were correlated with change
in depression scores. The typical stress-induced decrease in heart rate variability (HRV)
during exposure to the stressor was attenuated following acute saffron intake. Saffron
extract appears to improve subclinical depressive symptoms in healthy individuals
and may contribute to increased resilience against the development of stress-related
psychiatric disorders.
Clinical trials number: NCT03639831.
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INTRODUCTION
Depression is one of the most prevalent psychiatric disorder
and has been estimated to affect over 300 million people
worldwide, representing about 4.4% of the world’s total
population (1). Actual figures are likely to be higher as this
rate only includes diagnosed cases with subclinical levels of
mood disorders being also highly prevalent (2). Pharmacological
treatments exist, but a number of articles have emphasized
the inability of antidepressant medication to consistently
demonstrate superiority to placebo, in patients with mild
or moderate symptoms (3). Side effects of such treatments,
including nausea and drowsiness, are also common, especially at
medium to high doses in the case of selective serotonin reuptake
inhibitors (SSRIs) (4). Alternative treatments, such as natural
products or exercise for combating mood disorders, are therefore
being explored (5).
Among natural products, saffron, produced from the dried
stigma of Crocus sativus L., a perennial herb member of the
Iridaceae (Iris) family, appears a promising candidate. Saffron
stigmas are naturally rich in four major bioactive compounds:
crocin, crocetin (the hydrolysis product of crocin), picrocrocin,
and safranal (6) and are traditionally used in Asian (particularly
Persian) medicine to treat a range of physical ailments including
menstrual disorder, inflammation, and depressive symptoms
(7, 8). A meta-analysis of five clinical trials revealed a
treatment effect of saffron compared with placebo and similar
antidepressant efficacy when compared with antidepressant
medications (fluoxetine, imipramine), at a dose of 30 mg/day (all
studies) for at least 6 weeks in participants with major depressive
disorder (9). The extent to which the antidepressant effects of
saffron are replicated in individuals experiencing low mood is
currently unknown.
Certain environmental factors may be involved in the onset
and development of depressive symptoms. Among those factors,
chronic stressful life events during adulthood may activate or
amplify the expression of depressive symptoms (10). While
some people exposed to stressful events do not show signs or
symptoms of depression, others exposed to psychological stress
are vulnerable to depression (11). In response to psychological
stress, a series of neurobiological changes occur; abnormalities
in which are commonly reported in depressive patients (12).
Interestingly, saffron may reduce plasma levels of corticosterone
in response to stress in both acute and chronic rodent studies
(13, 14), suggesting potential modulation of the hypothalamic–
pituitary–adrenal (HPA) axis following this extract. In humans,
to our knowledge, no study has evaluated the effect of saffron
in response to induced acute stress. A single study has shown
that healthy female humans exposed to saffron aroma for 20min
also experienced a decrease in salivary cortisol levels, which was
accompanied with a decrease in anxiety measured using the
State–Trait Anxiety Inventory (STAI) (15).
Overall, the evidence suggests that the efficacy of saffron with
regards to the modulation of mood may extend beyond clinical
populations and might also include the attenuation of stress
responses. This research is important given that the incidence
of major depression has been shown to be higher in patients
with diagnosed subclinical depression (16). Therefore, the aim of
the present study was (1) to assess the chronic effect of saffron
on emotional well-being evaluated by a series of questionnaires
in healthy adults self-reporting low mood and (2) to evaluate
the acute effect of saffron extract in response to a psychosocial
stressor through psychological and physiological parameters.
MATERIALS AND METHODS
Design
This study adopted a randomized, placebo-controlled, double-
blind, parallel groups design, in which the acute and chronic
effects of saffron extract and placebo were assessed before,
during, and after a laboratory stressor, the ObservedMultitasking
Stressor (OMS) on days 1, 14, 28, and 56 after treatment
consumption. This study was conducted according to the
guidelines laid down in the Declaration of Helsinki, and
all procedures involving human participants were approved
by the Northumbria University’s Department of Psychology
Ethics Committee (Ref: 1028). Written informed consent was
obtained from all participants. The trial is registered at
ClinicalTrials.gov (NCT03639831).
Participants
Seventy-three participants aged 18–60 years who self-reported
feelings of anxiety and/or stress and low mood in their
daily lives were recruited within Newcastle-upon-Tyne and
the surrounding areas. The study was advertised using emails
distributed to the research center’s participant database and
Northumbria University’s internal distribution lists, along with
adverts placed on social media. Participants who complied
with the diagnosis criteria (using self-report questionnaires)
of any psychological pathology (e.g., depression, generalized
anxiety disorder) or diagnosed (by a medical practitioner)
for such pathology within the previous 3 years were not
eligible. As well, exclusion criteria were the following: body
mass index (BMI) ≤18.5 or ≥30 kg/m2; uncorrected visual
impairment; food allergies/insensitivities; an hormonal status
likely to induce an unstable/fluctuating emotional state (e.g.,
menopausal transition); presence of life event likely to induce
unstable/fluctuating emotional state (e.g., change of professional
function/ situation, death of a family member, divorce, surgery);
high blood pressure (systolic over 159mm Hg or diastolic over
99mm Hg); pregnant women, seeking to become pregnant,
or lactating; worked night shifts; engaged in high levels
of physical activity (to avoid bias in the salivary cortisol
measures); consumed >500mg caffeine per day; current
smokers; and dietary supplement use 2 weeks before enrolment.
A number of health conditions were also excluded; a full
list of inclusion/exclusion criteria is presented in the Online
Supplementary Material.
In order to recruit a sample of participants who may
be experiencing subclinical levels of depressive symptoms,
participants were administered a number of questionnaires at the
screening visit with the following exclusion thresholds in a first
attempt: >36 on the Penn State Worry Questionnaire (PSWQ)
(17); >13 on the Perceived Stress Scale (PSS-10) (18); <10 on
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FIGURE 1 | Participant disposition flowchart. ITT, intent to treat population; PP, per protocol population; POMS, Profile of Mood States questionnaire; BMI, body mass
index.
the Generalized Anxiety Disorder 7-item questionnaire (GAD-7)
(19); <10 on the Patient Health Questionnaire 9-item (PHQ-
9) (20), and ≥35 on the State-Trait Anxiety Inventory State
(STAI) (21). However, due to initial difficulties with recruitment,
the following inclusion criteria were subsequently adopted: total
score ≥40 on the Profile of Mood States 2 (POMS) (22), <16 on
the GAD-7 questionnaire, and≤10 on the PHQ-9 questionnaire.
Seven participants who were randomized to treatment according
to the initial exclusion criteria were later withdrawn from the
study. Fifty-six participants were included in the final per-
protocol analysis set (see Figure 1). All participants gave their
written informed consent before inclusion in the study and were
compensated £230 for their time and any travel costs upon
completion of the study. Data were collected between November
2017 and November 2018.
Participant demographics and baseline characteristics are
shown in Table 1.
Treatment and Dosing Schedule
Participants were randomly allocated to receive 30mg saffron
extract (Safr’InsideTM) standardized in SafromotivinesTM [a blend
of more than 25 active compounds, including safranal >0.2%
(analyzed with HPLC)] or a placebo. Each saffron capsule
contained 15mg saffron extract plus 345mg maltodextrin,
and each placebo capsule contained 350mg maltrodextrin.
Treatments were randomized in accordance with a computer-
generated randomization list that was generated by an academic
colleague at Northumbria University who had no further
involvement in the study. Treatments were delivered to the
investigational site identified only by their randomization
code. Treatments were provided by Activ’Inside in bottles
and were identical in appearance to ensure that participants
remained blind to the treatment they had received. Non-stratified
randomization of participants took place at the first testing study
visit (day 1), where they were allocated to the next sequential
randomization number. Blinding remained in place until all
of the data, bar the urinary crocetin data, had been analyzed
according to the statistical analysis plan.
Participants consumed the first dose (two hard shell capsules)
of their 56-day treatment within the laboratory during their visit
(day 1). They then continued to consume this treatment daily,
at home. One capsule was taken in the morning and another in
the evening, at least 30min after a meal. Participants completed a
dosing diary each day with the time of each capsule consumption
noted. These instructions were emphasized at training, at the end
of the acute lab visit days, and were printed on their treatment
bottle label. Treatment on days 14 (±2 days), 28 (±3 days),
and 56 (±3 days) was again consumed in the laboratory (two
capsules) prior to completing the OMS.
Observed Multitasking Stressor
The OMS incorporates two elements that have previously been
shown to engender a stress response in laboratory studies:
extended multitasking and social evaluation. The OMS has
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TABLE 1 | Baseline characteristics by treatment group.
Measure Treatment Mean SD p
Sex ratio (male/female) Placebo 6/20
Saffron 10/20
Age (years) Placebo 28.62 9.49 0.80
Saffron 28.00 9.11
Education (years) Placebo 16.69 2.51 0.72
Saffron 16.98 3.39
Cigarettes (number/week) Placebo 0.19 0.98 0.32
Saffron 0.90 3.45
Fruit and veg consumption (portions/day) Placebo 4.21 1.52 0.35
Saffron 3.82 1.62
Alcohol consumption (units/day) Placebo 0.72 0.80 0.70
Saffron 0.81 0.69
Caffeine consumption (mg/day) Placebo 176.08 87.44 0.48
Saffron 198.03 133.79
Systolic BP (mm/Hg) Placebo 118.56 11.55 0.57
Saffron 116.67 13.00
Diastolic BP (mm/Hg) Placebo 77.69 8.09 0.26
Saffron 75.13 8.56
Heart Rate (beats per minute) Placebo 71.25 11.15 0.43
Saffron 68.98 10.00
BMI (kg/m2 ) Placebo 23.15 2.68 0.81
Saffron 22.97 2.91
GAD-7 Score Placebo 6.58 3.40 0.70
Saffron 6.90 2.92
PHQ-9 Score Placebo 5.92 2.87 0.25
Saffron 6.77 2.56
POMS Score Placebo 64.60 22.27 0.69
Saffron 62.34 18.31
BP, blood pressure; GAD-7, Generalized Anxiety Disorder-7 item questionnaire; PHQ-9, Patient Health Questionnaire-9 item questionnaire; POMS, Profile of Mood States. p-values
were derived from independent measures t-tests (or Mann–Whitney U-tests in the case of non-normally distributed data).
previously been shown to provoke a psychological stress response
across repeated administrations (23). Briefly, the OMS comprised
verbal completion of three serial subtraction tasks (3, 7, and 17’s)
for 4min each (12min in total). Participants were instructed
to count backwards from a given randomly generated number
between 800 and 999 aloud, as quickly as possible. Performance
of the task was scored for the total number of correct subtractions
and incorrect subtractions. In the case of incorrect responses,
subsequent responses were scored as correct if they were correct
in relation to the new number. During the serial subtraction
tasks, participants also completed a computerized tracking task,
in which they were required to use the mouse to move a cursor
to attempt to track an asterisk that followed a smooth, random
on-screen path; participants were instructed to keep the cursor as
close to the asterisk as possible.
These tasks were performed in front of a panel of three
“judges” who maintained a neutral demeanor throughout the
assessment. The computer screen, showing the tracking task, was
projected onto a screen to give the impression that the panel
was closely monitoring progress. Before and immediately after
completing the OMS, mood was assessed with the STAI (State)
and computer-delivered visual analog scales (VAS) indicating
the participants’ current level of stress, anxiety, relaxation, and
calmness (see below). Thesemeasures ofmoodwere also repeated
every 15min (VAS) or 30min (STAI, State) after completion of
the stressor, as per Figure 2. A full description of the OMS can be
found in the Online Supplementary Material.
Mood and Well-Being Measures
Before undergoing the OMS, participants completed a number
of psychological questionnaires: the POMS-2 (22), STAI (Trait)
(21), the PSWQ (17), the PSS-10 (18), the COPE Inventory
(COPE) (24), the Hospital Anxiety and Depression Scale (HADS)
(25), and the World Health Organization Quality of Life
questionnaire (WHOQOL-BREF) (26). The POMS “total mood
disturbance” (TMD) score was the primary outcome measure.
The VAS that were completed before and after the OMS
were presented using the Computerized Mental Performance
Assessment System (COMPASS, Northumbria University,
Newcastle upon Tyne, UK). Line scales anchored “not at
all” (left-end) and “extremely” (right-end) were presented to
participants who were required to mark a cross on a line using a
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FIGURE 2 | Testing timeline of the study visits. Participants completed a battery of questionnaires predose on arrival; the State–Trait Anxiety Inventory (STAI)-State,
visual analog scales (VAS), and saliva samples were completed preobserved multitasking stressor (OMS). Galvanic skin response (GSR) and heart rate were collected
for 5min during completion of the questionnaire battery and again during the OMS. Collection of saliva samples and completion of VAS was repeated immediately and
at 15-min intervals poststressor, respectively; the STAI-State was completed immediately and at 30-min intervals. POMS-2, Profile of Mood States 2; PSWQ, Penn
State Worry Questionnaire; PSS-10, Perceived Stress Scale-10; WHOQOL-BREF, World Health Organization Quality of Life questionnaire; HADS, Hospital Anxiety and
Depression Scale.
mouse to indicate their current level of stress, anxiety, relaxation,
and calmness. These were scored as percentage along the line
from left to right.
Biological Samples Analysis
Salivary Cortisol and Alpha Amylase Analysis
Saliva samples were obtained using salivettes (Sarstedt Ltd,
UK) to measure cortisol and alpha-amylase response. Seven
samples were collected per testing visit with a sample taken
prior to completion of the OMS and another immediately after.
Remaining samples were collected at 15-min intervals post
stressor. Once collected, samples were spun down at 1,000 g for
2min. Samples were transferred into Eppendorfs and frozen at
−80◦C until analysis. Before assaying, the samples were thawed;
cortisol and α-amylase levels were measured using ELISA kits
and carried out according to the instructions of the supplier
(Salimetrics Ltd, UK). The coefficients of variability for the
cortisol and α-amylase assays were 20 and 15%, respectively.
Urinary Crocetin Analysis
Samples were collected from the first urination in the morning
prior to attending the lab for each visit. Participants were
instructed to urinate into a measuring jug, note down the
total amount in milliliters (ml), and the time of collection.
If participant needed to urinate during the night, this was
collected using the same method as above; however, it was then
transferred into a storage vessel and refrigerated overnight. In the
morning, it was mixed with the first urination of the morning,
and the entire vessel was brought to the lab. Participants were
provided with freeze-able pouches to keep their samples cool
on their journey to the lab. Samples were frozen at −80◦C and
shipped to France for crocetin analysis. For identification and
quantification of urinary crocetin, samples of 10 participants
receiving placebo and 20 participants receiving saffron extract
were saponified, extracted with ethyl acetate, and were analyzed
by ultrahigh performance liquid chromatography tandem
mass spectrometry (UHPLC-MS/MS) (ThermoFisher Scientific,
Courtaboeuf-France) according the modified chromatographic
conditions of Zhang et al. (27). Briefly, chromatographic
separation of the analytes was performed on a C18 column
(100mm × 2.1mm, 3µm, Atlantis R©T3, Waters). The aqueous
mobile phase (solvent A) contained 0.1% formic acid, while
the organic mobile phase (solvent B) was acetonitrile. The
negative mode was selected, and the analytes were quantitatively
monitored using multiple reaction monitoring (MRM). The
MRM transition for crocetin was m/z 327.145 → 239.30. The ion
spray voltage was optimized and maintained at 3,000V. The
crocetin concentration in urine samples was calculated using a
standard linear curve at several crocetin concentration (from 0.09
to 0.90 ng/ml). The limit of detection and quantification were
0.04 and 0.13 ng/ml, respectively, with an intra-assay precision
CV of 4% and an interassay variability and precision CV
of 8%. The level of creatinine was determined by a coupled
enzymatic and colorimetric essay (Sigma-Aldrich, St Louis, USA)
for each urinary sample to take into account different urine
concentrations between volunteers. The quantity of urinary
crocetin was therefore expressed in nanograms of crocetin per
milligram of creatinine.
Galvanic Skin Response and Heart Rate
Galvanic skin response (GSR) and heart rate (HR) weremeasured
using the Vilistus Digital Sampling Unit (Durham Systems
Management Limited, UK). The GSR sensors, which measured
relative changes in skin conductance, were attached to the middle
and forth fingertips of the participants’ non-dominant hand using
Velcro straps. The HR sensor clip, whichmeasured blood volume
Frontiers in Nutrition | www.frontiersin.org 5 February 2021 | Volume 7 | Article 606124
Jackson et al. Effect of Saffron on Mood and Stress Response
pulse, was placed on the tip of the index finger or thumb of
the non-dominant hand. These sensors were attached at least
1min prior to the commencement of recording to allow for
stabilization of the readings. The unit measured at a rate of 32
or 128 samples per second for GSR and HR, respectively. The
software that accompanies this device also calculates a number
of HRV measures including root mean square of the successive
differences (RMSSD) HRV index (an indication of the variability
within the heart rate across the session calculated from the inter-
beat interval plot), pnn50 (mean number of times per hour in
which the change in consecutive normal sinus intervals exceeds
50ms), and a stress index (the ratio between the parasympathetic
and sympathetic tone). No sensitivity data were provided by the
manufacturer however this device has been successfully used by
our lab and others in the assessment of changes in electrodermal
activity in response to an intervention (23, 28, 29).
Satisfaction and Tolerance Questionnaire
At the final visit, participants were asked to complete an in-
house product satisfaction and tolerance questionnaire. The
questionnaire aimed to ascertain if participants had experienced
any changes in their libido and any beneficial effects of taking the
treatment on their mood and well-being. It also inquired whether
the participants found the product to be well-tolerated and easy
to use. Finally, participants were asked to guess which treatment
they had been given.
Procedure
Participants were required to attend the Brain, Performance and
Nutrition Research Centre (Northumbria University) for five
visits. The first visit comprised a screening and training session;
once written informed consent had been obtained, participants
were screened according to the inclusion/exclusion criteria.
Eligible participants then provided lifestyle and demographic
data, and their height, weight, and blood pressure weremeasured.
They completed a short training session in which they practiced
the serial subtraction tasks, the computerized tracking task, and
computerized VAS, along with a practice saliva sample (not
analyzed), and completed the STAI (Trait) questionnaire. At the
end of this visit, participants were provided with urine collection
containers and instructions for urine collection.
Within 2 weeks of the screening visit, participants returned
to the laboratory for their first testing visit at an agreed time in
the afternoon that remained consistent across all testing visits.
Participants completed urine collection on the morning of the
testing visit and brought this sample with them to the laboratory.
Participants arrived at the laboratory having consumed their
normal breakfast and lunch and having consumed their normal
amounts of caffeinated products, which was documented on a
food diary. The diary contained basic dietary information for
the day of the testing visit as well as the previous day including
type of food/drink consumed and when. These data were used to
check caffeine consumption restrictions and that an equivalent
diet was consumed prior to all visits. Once participants arrived
at the lab, they were not permitted to eat any food or chewing
gum. Continued compliance with the inclusion/exclusion criteria
was assessed via the Case Report Form. Participants then
completed the POMS, STAI (State), PSWQ, PSS-10, HADS,
COPE, and WHOQOL-BREF.
Participants consumed their first dose of the allotted treatment
and completed the pre-OMS STAI (State), along with the
computerized VAS. Following this, they provided a saliva sample.
At 15min postdose, participants were taken to an “interview”
room where they underwent the OMS for 15min in front of a
panel of three observers. GSR and HR were measured during
the OMS following a predose baseline assessment of 5min that
was collected during completion of the questionnaires. Saliva
samples were provided immediately after the OMS and at 15-min
intervals up to 75min post OMS (i.e., 105min post dose) with the
VAS being completed at the same time points. The STAI (State)
was completed immediately after the OMS and at 30 and 60min
post OMS. The full assessment timeline during all study visits is
shown in Figure 2.
In the interim periods between each of the testing visits,
participants were instructed to take their daily treatment and
complete a treatment diary on a daily basis. Participants were
reminded to consume the same foods and beverages consumed
on the day 1 testing visit for all subsequent testing visits. The
procedure during the subsequent three visits was identical to that
of day 1, with the exception that participants returned treatment
diaries and unused capsules. On day 56, the STAI (Trait) was
completed along with a tolerance and satisfaction questionnaire.
Statistical Analysis
All outcomes were analyzed using SPSS (version 24.0, IBM corp.)
unless otherwise specified.
Sample Size Calculation
To detect a difference between placebo and saffron of 22 points
(SD= 30) on the Total Mood Disturbance outcome of the POMS
(the primary endpoint) (22), with a two-sided 5% significance
level and a power of 80%, a total sample size of 72 participants
was deemed necessary. This total included allowance for an
anticipated 15% dropout rate.
Treatment Compliance and Tolerance, Blinding, and
Baseline Differences
Independent measures t-tests (or Mann–Whitney U-tests in the
case of non-normally distributed data) were used to compare
treatment groups at baseline and treatment compliance. A chi-
squared test was used to assess the success of the double-blind
procedure and to analyze the tolerance data.
Chronic Assessment of Mood and Well-Being
Questionnaires
For the pre-OMS questionnaires (POMS, HADS, STAI-State,
PSWQ-2, PSS-10, COPE, and WHOQOL-BREF), change from
day 1 scores for days 14–56 were analyzed using the MIXED
procedure in SPSS for between-group differences including the
terms Treatment and Visit and their interaction as a fixed factors.
With regard to the primary outcome measure, the between group
difference at day 56 on the POMS-TMD score was analyzed using
Bonferroni-adjusted pairwise comparisons following the linear
mixed model analysis.
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Acute Response to the OMS
For the STAI (State) and VAS data, change from baseline scores
(post-OMS value minus pre-OMS value) were analyzed for
between group differences using theMIXED procedure including
the terms Treatment, Assessment, andVisit and their interactions
as fixed factors.
Change from baseline values for GSR (µSiemens) and HR
(beats per minute) (during OMS value minus pre-OMS value)
were analyzed for between-group differences including the terms
Treatment, Task, and Visit and their interactions as fixed factors.
The number of total correct answers and errors for serial
subtractions tasks and the tracking cost for tracking task were
analyzed including the terms Treatment, Visit, and Task and
their interactions as fixed factors. For the HRV outcomes, due to
significant deviation from normality of the residuals, some HRV
measures were log or square root transformed. Between-group
differences in transformed or natural HRV measures during the
OMS were analyzed using a linear mixed model including the
terms Treatment and Visit, the interaction Visit × Treatment,
and the baseline HRV measures as fixed factors.
Salivary Cortisol and α-Amylase
Incremental area under the curve (iAUC) and net iAUC were
calculated for salivary cortisol and salivary alpha-amylase. First,
the incremental AUC (iAUC), i.e., the area over the limit of
quantification under the curve and ignored area beneath the
curve, was calculated with the linear up-log down method of
non-compartmental analysis, with the PKsolver add in for Excel
(30). Second, the net iAUC, i.e., the positive area minus the
negative area over the pre-OMS value, was calculated using
the linear trapezoidal method of non-compartmental analysis
(31). iAUC, net iAUC, and the maximum change from sample
1 were analyzed for between group differences including the
terms Treatment and Visit and their interaction as fixed factors.
Wilcoxon signed-rank test was used in post-hoc comparisons
to assess the difference at each visit, within treatment group.
Time to maximum concentration (Tmax) was analyzed non-
parametrically using the Friedman test to assess equivalence of
ranks within each treatment group across the four visits.
Urinary Crocetin
Urinary crocetin (ng/mg of creatinine) under the limit of
detection (LOD) were imputed by LOD/
√
2 (32). Urinary
crocetin was analyzed with a linear mixed model with Treatment,
Visit, and their interaction, after log-transformation due to
non-normally distributed data. Spearman correlation between
variation in urinary crocetin (difference day 56–day 1) and
variation in POMS depression T score (difference day 56–day 1)
was performed.
OMS Validation
In order to confirm that participants found the OMS protocol
stressful, STAI-State, VAS anxiety, salivary cortisol, and α-
amylase were compared before, during, and after the OMS. The
models were set up as above, including the terms Treatment,
Visit, and Assessment and their interactions as fixed factors.
Subject was included as a random factor.
RESULTS
Treatment Compliance and Tolerance,
Blinding, and Baseline Differences
There were no significant between-group differences on any
baseline demographic measure (Table 1, all p > 0.05). Overall
compliance, assessed by pill count, was excellent (97% in
the placebo group and 96% in the saffron group); a t-
test confirmed that compliance was not significantly different
between the treatment groups (p = 0.60). Success of blinding
was confirmed via treatment guess at the end of the study.
Fifty-two percent of participants in the placebo group and
41% of participants in the saffron group believed they had
received placebo. Chi-squared analysis confirmed this to be a
non-significant difference (p = 0.40). A lack of any between-
group differences on the satisfaction questionnaire indicated
that participants who received saffron found the product to be
as tolerable as the placebo, and a similar number of adverse
events were reported by each group (none were classified
as serious).
Day 1 between-group differences were analyzed for the
pre-OMS questionnaire and GSR outcomes. Results indicated
that participants who received saffron had significantly higher
religious coping (U = 462.5, p = 0.005) and positive
reinterpretation coping [F(1,53) = 4.81, p = 0.03] on the COPE
questionnaire before treatment.
Effect of Chronic Saffron Supplementation
on Emotional Well-Being
There was no effect of treatment nor treatment× visit interaction
on the primary outcome measure, T-score of POMS Total mood
disturbance. However, there was a significant effect of treatment
on the POMS Depression subscale (T-score), with participants
who received saffron seeing a greater reduction in their subjective
experience of depressed mood from predose day 1 across the
visits than the placebo group [F(1,51.58) = 4.18, p = 0.05]. See
Figure 3.
A significant Treatment × Visit interaction was observed
for the domain Social Relationships of the WHO quality
of life questionnaire [F(2,63.65) = 3.88, p = 0.03]. Pairwise
comparisons revealed that participants receiving saffron had a
higher social relationship score compared to placebo at 56 days
post-supplementation (p= 0.007) (see Figure 4A).
A significant treatment effect was observed for positive
reinterpretation coping [F(1,51.71) = 7.25, p = 0.010] with
participants who received saffron having an attenuated increase
in positive reinterpretation compared to placebo (see Figure 4B).
A significant Treatment × Visit interaction was observed
for the denial coping strategy [F(2,65.71) = 3.39, p = 0.04].
Pairwise comparisons revealed a borderline difference on day 14;
participants who received saffron had a higher score compared
to placebo at 14 days post-supplementation (p = 0.09) (see
Figure 4C).
Finally, chronic saffron supplementation induced a significant
change in urinary crocetin level (p < 0.0001) (see Figure 5).
Indeed, participants who received saffron had a higher mean
level of urinary crocetin (0.46 ± 0.42 ng/mg of creatinine)
than those receiving placebo (0.05 ± 0.05 ng/mg of creatinine)
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FIGURE 3 | Change from baseline day 1 responses on the primary outcome measure (A) Profile of Mood States (POMS) Total mood disturbance and (B) the POMS
Depression subscale by treatment and visit. No effects were observed on the primary outcome measure. A main effect of treatment was observed for depression (p =
0.05). Estimated means ± standard error are shown.
after supplementation, all visits taken together (days 14–56). A
significant correlation between variation in POMS depression T-
score and variation in urinary crocetin level (day 56–day 1) was
observed (Spearman ρ =−0.50, p= 0.008).
Effect of Saffron in Response to a
Psychosocial Stressor
Validation of the OMS
Analysis of the VAS and STAI-State revealed that all participants,
irrespective of treatment, experienced an increase in subjective
anxiety in response to the OMS protocol, which was coupled
with an effect of assessment for salivary cortisol and α amylase,
indicative of a physiological stress response (effect of assessment
p < 0.001 for all outcomes, see Figure 6).
Acute Response to the Stressor
Taking into account the baseline measure, a significant treatment
effect was observed for the heart rate variability, RMSSD during
OMS. Participants who received placebo had a decrease in
RMSSD during OMS, whereas participants receiving saffron
experienced no change in RMSSD [F(1,44.1) = 9.92, p = 0.003].
See Figure 7.
A significant Treatment × Assessment interaction was
observed for the relaxed VAS [F(5,955.05) = 2.75, p = 0.02].
Regardless of visit, pairwise comparisons revealed a trend for
participants who received saffron to rate themselves as feeling less
relaxed 105min postdose (p= 0.07). See Figure 8.
With regards to salivary cortisol, the Friedman test within
the saffron treatment group indicated that the change in Tmax
salivary cortisol concentration from baseline was different across
visits [Friedman’s Q (3) = 8.72, p = 0.03]. However, post-hoc
pairwise comparisons did not reveal any significant differences
between visits (data not tabulated).
No other effects of Treatment nor Visit × Treatment
interaction were observed. With regards safety, equal numbers
of participants reported adverse events (20 in each group). None
of these adverse events were serious, and none of them led to
premature withdrawal or exclusion from the study. However,
there was a greater number of incidents of gastrointestinal upset
in the saffron group compared to the placebo group (5 vs. 0).
Tables of all outcome measures can be found in the Online
Supplementary Material.
DISCUSSION
The current study explored the effects of a proprietary saffron
extract (Safr’InsideTM) on emotional well-being following 14,
28, and 56 days supplementation in healthy adults experiencing
low mood as measured using the POMS. Effects of the extract
on physiological and psychological response to a psychosocial
stressor (OMS) were also measured following a single acute dose
and postdose at the time points mentioned above. The results
revealed several beneficial effects of saffron on subjective mood
and quality of life measures, with the clearest finding reflecting a
greater reduction in the depression scale of the POMS compared
to placebo. This was accompanied by an improvement in social
relationships on day 56. In addition, the stress-induced reduction
in HRV (RMSSD) during the OMS observed in the placebo group
was absent in those receiving saffron.
Turning first to the general mood measures that were
collected predose on each of the study visits, compared
to placebo, participants who received saffron experienced a
greater reduction in depression scores. This finding reflects a
growing body of evidence supporting the use of saffron in the
treatment of depression in patient populations (6, 33). However,
demonstration of the efficacy of saffron extract supplementation
on depressive symptoms in a healthy population self-reporting
low mood is completely new. Indeed, to our knowledge, only one
other study has reported a positive effect of saffron on depressive
symptoms in a healthy population (34). The comparable effects
of saffron to other pharmacological treatments of depression has
led to the conclusion that it may act on similar neurotransmitter
systems, although the exact mechanisms are yet to be clarified
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FIGURE 4 | Change from baseline day 1 responses on the chronic
mood/well-being questionnaires by treatment and visit; (A) World Health
Organization Quality of Life Questionnaire (WHOQOL) Social relationships
subscale, (B) COPE questionnaire Positive reinterpretation subscale, and
(C) COPE questionnaire Denial subscale. Estimated means ± standard error
are shown. **p < 0.01; t, p < 0.10.
(35). For example, Wang et al. (36) identified crocin 1 in
an aqueous extract of saffron stigma, the administration of
which was associated with antidepressant-like effects in mice
who performed a forced swimming test (reduced immobility
FIGURE 5 | Urinary crocetin levels collected at baseline and at 14, 28, and 56
days post-supplementation. Data are means ± standard deviation of raw
values. Urinary crocetin levels were expressed by milligrams of creatinine.
time). Crocin was also identified as an antagonist of the non-
selective serotonin receptor agonist mCPP, which is known to
induce excessive grooming in rats, and exacerbate symptoms
in human patients with obsessive compulsive disorders (37).
Other studies concluded that saffron may act by a combination
of serotoninergic, noradrenergic, and dopaminergic system
activation (38). In our study, we found that changes in urinary
crocetin, probably due to changes in blood saffron metabolites,
were strongly associated with variation in POMS depression T-
score. This novel finding adds further evidence linking specific
bioactive constituents of saffronwith subjectivemood in humans.
A positive effect of saffron on social relationships ratings was
observed at day 56. This finding could be interpreted in the
context of the concurrent improvement in depression scores
observed in participants who received saffron. Previously, it has
been shown that participants who exhibit greater depressive
symptoms also report a higher number of negative social
interactions and a lower sense of belonging in social interactions
(39). It follows then that an improvement in depressive mood
may manifest in enhanced social relationships. What is less
clear is why the aforementioned change in mood would not be
reflected in improvements in other quality of life measures. As
this is the first time an effect of saffron on an individual’s life
beyond their mood state has been observed, further investigation
is recommended.
Concerning the other measures, no evidence of an effect
of saffron on subjective anxiety as assessed by the STAI
questionnaire or anxiety scale of the HADS was found. An
anxiolytic effect of saffron has previously been demonstrated
in preclinical studies (37, 40) and in patients with mild to
moderate depression (38, 41). Further, reduced tension (POMS)
was reported by Kell et al. (34), suggesting a less consistent
anxiolytic effect of saffron in healthy individuals self-reporting
low mood. With regards to the current study, the context in
which the predose mood and well-being questionnaires were
completed by participants may also be important. Participants
completed these questionnaires in full knowledge that they were
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FIGURE 6 | Effect of the Observed Multitasking Stressor (OMS) on (A)
State–Trait Anxiety Inventory (STAI) (State), (B) anxiety measured using visual
(Continued)
FIGURE 6 | analog scale (VAS), (C) salivary cortisol, and (D) salivary α
amylase. Data are pooled across treatment groups and visits. Estimated
means ± standard error are shown derived from a linear mixed model
including the terms treatment, visit, and assessment.
FIGURE 7 | Effect of treatment on heart rate variability (root mean square of
the successive differences) during the resting 5-min baseline and observed
multitasking stressor (OMS). Estimated means ± standard error are shown.
**p < 0.01.
FIGURE 8 | Effect of treatment on the Relaxed visual analog scale (VAS) at
each assessment point. Estimated means ± standard error are shown. t, p <
0.10.
going to complete the OMS, and this may have influenced their
responses on these questionnaires. Subjective well-being has been
shown to correlate with current mood (42) and also to be affected
by experimental manipulation (43). It may be that anticipation
of the OMS, evidenced by the pattern of response in the cortisol
measure, masked an effect of treatment on anxiety measures or
indeed any of the other subjective measures and is a limitation of
the current design.
Although it seems that participants had anticipated the
stressor, analysis of OMS data revealed that all participants,
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irrespective of treatment, found the protocol to be indeed
stressful, evidenced by the observed increase in subjective anxiety
immediately after completing the stressor. The significant effects
of saffron in response to this psychosocial stressor were limited
to attenuating a decrease in the HRV measure, RMSSD. This
time-domain measure of beat-to-beat variability is thought to be
primarily mediated by activity of the parasympathetic nervous
system (PNS) (44) and is reduced during acute stress (45).
Variation in RMSSD in response to OMS in the placebo group
was in accordance with those observed following a moderate
psychosocial stressor (45, 46). It is interesting that this measure
of physiological response to stress was the only parameter to be
modulated by saffron and perhaps suggests a specificity of the
action of saffron on the PNS. Specifically, other HRV measures
and GSR are predominantly modulated by sympathetic activity
or antagonistic control of both the sympathetic nervous system
and the PNS (44, 47, 48). Acetylcholine is the predominant
neurotransmitter of the PNS, and it is possible that the observed
effect of saffron, and specifically the constituent safranal, is
underpinned by increased cholinergic activity (49). Anxiolytic
effects in response to an acute lab-based stressor have also been
demonstrated following monoterpenoid plant extracts such as
those derived from sage and lemon balm (50, 51). Interestingly,
an acute 200 µl dose of Lavandula angustifolia (lavender) oil—a
source of the monoterpene linalool—modulated RMSSD during
viewing of an anxiety-inducing film clip, but only in females
(52). However, reduced GSR, HR, and increased HRV (pNN50,
which correlates highly with RMSSD) were reported in all
participants following a neutral film clip. The authors suggest that
lavender may modulate serotonin pathways that interact with
cholinergic systems in a similar fashion as selective serotonin
reuptake inhibitors (SSRIs) such as fluoxetine and citalopram,
given evidence that HRV increases following treatment with this
class of drugs in patients with panic disorder (53). The similar
pattern of effects of saffron compared to SSRIs in the treatment
of depression in clinical trials (9) certainly adds weight to this
suggestion with regard the current findings.
Safranal may also modulate HRV through its action on
GABAergic systems (54). In one study, peripherally administered
safranal abolished the seizure effects of pentylenetetrazol that
the authors suggested could be mediated via the GABAA-
benzodiazepine receptor complex (55). These authors
also noted that related monoterpenes such as linalool and
terpineol potentiate GABA and competitively inhibit glutamate
receptors, further strengthening this argument. Interestingly,
acute administration of both normal and GABA-fortified
oolong tea was found to increase RR intervals and decrease
subjective ratings of stress in healthy participants, with a
greater effect seen in the GABA-fortified tea condition (56).
As HRV is a measure that reflects autonomic health and
an indicator of psychological resilience (44), the observed
effect of saffron on RMSSD reported here may have far-
reaching health benefits. It would be interesting to investigate
whether this effect was observed over a longer period
(e.g., 24-h monitoring), suggesting modulation of overall
parasympathetic tone, or if the effect is only observed during
acute stress.
Of course, the study is not without its limitations. It is
recognized that laboratory-based stressors have inherent
limitations in eliciting robust psychobiological stress responses
that mimic those experienced in real-world situations—
especially with repeated measurement—which have been
discussed elsewhere (57). The nature of the study sample should
also be considered. Identifying potential participants with
subclinical mood disturbance resulted in a comparatively small
number of individuals with a very specific response pattern
to the screening questionnaires being enrolled to the trial.
Although it was the aim of the study to investigate the effects of
saffron in otherwise healthy participants with subclinical mood
disorders, it does of course limit the relevance of the findings
beyond this population, and the effects in wider general or
clinical populations are unknown. Furthermore, the inclusion
and exclusion criteria themselves were not based on formal
diagnostic criteria, and the link between the selected criteria and
risk of developing depression is also unknown. Lastly, while we
attempted to limit the risk of bias by excluding certain conditions
or lifestyle behaviors, it must be acknowledged that it is also
important to examine the effectiveness of saffron and whether
its effects are increased or diminished when coupled with other
mood-associated variables.
In conclusion, saffron extract appears to reduce depressive
mood in healthy individuals experiencing subclinical mood
disturbance and adds to the growing literature showing
consistent benefits of saffron on depression outcomes across
both clinical and non-clinical populations. Importantly, the
beneficial effect of saffron on heart rate variability in response to a
psychosocial stressor—shown for the very first time in the present
study—suggests that this natural extract may be particularly
relevant for increasing resilience against the development of
stress-related psychiatric disorders. Further research is needed
to identify the exact mechanisms underpinning these effects
in humans.
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